Application Note

A Platform Standard For Viral Vector Manufacturing And Commercialization

By Eva Fong, Principal Scientist and Jessica Hilmoe, Technical Leads Manager, MilliporeSigma

bioreactor in the bio lab-iStock-486734678

Interest in cell and gene therapies is continuing to grow as regulatory approvals increase and the clinical pipeline expands. As these therapeutics moves toward indications with larger patient populations, the pressure to improve manufacturing efficiency and robustness is rising.

One important component for cell and gene therapy manufacturing is the large-scale production of viral vectors. Specifically, vectors need to be produced efficiently and meet set quality attributes. To meet these goals, platform technologies must be developed and implemented to support the rigors of commercial manufacturing.

We recently launched the VirusExpress® Lentiviral Production Platform to produce industry-leading vector harvest titers while improving speed and commercial readiness for manufacturers. In addition, we are currently developing an equivalent program offering of an upstream platform and templated process to achieve the same benefits for Adeno-Associated Viral (AAV) gene therapies. Key features of our templated process approach include process validation and continued process verification, we discuss in more detail here.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online